Cited by

• Efficacy and safety of low-dose corticosteroids combined with leflunomide for progressive IgA nephropathy: a systematic review and meta-analysis.

  Zhang D, Xia B, Zhang X, Liang P, Hu X. Zhang D, et al. BMC Urol. 2024 Mar 11;24(1):56. doi: 10.1186/s12894-024-01438-3. BMC Urol. 2024. PMID: 38468247 Free PMC article.
• Characterization of glomerular basement membrane components within pediatric glomerular diseases.

  Chen D, Zhou X, Gan C, Yang Q, Chen W, Feng X, Zhang T, Zhang L, Dai L, Chen Y, Yang H, Wang M, Jiang W, Li Q. Chen D, et al. Clin Kidney J. 2024 Feb 14;17(3):sfae037. doi: 10.1093/ckj/sfae037. eCollection 2024 Mar. Clin Kidney J. 2024. PMID: 38455522 Free PMC article.
• GWAS-follow-up Studies Identified a Connection between Abnormal LIF/JAK2/STAT1 Signaling and Overproduction of Galactose-Deficient IgA1 in the Tonsillar IgA1-Secreting Cells from Patients with IgA Nephropathy.

  Yamada K, Novak J, Suzuki Y. Yamada K, et al. J Clin Res Bioeth. 2024;15(1):478. Epub 2024 Jan 22. J Clin Res Bioeth. 2024. PMID: 38440092 Free PMC article. No abstract available.
• Advancing the application of the analytical renal pathology system in allograft IgA nephropathy patients.

  Liu X, Fang H, Liang D, Lei Q, Wang J, Xu F, Liang S, Liang D, Yang F, Li H, Chen J, Ni Y, Xie G, Zeng C. Liu X, et al. Ren Fail. 2024 Dec;46(1):2322043. doi: 10.1080/0886022X.2024.2322043. Epub 2024 Feb 29. Ren Fail. 2024. PMID: 38425049 Free PMC article.
• Sequential administration of paricalcitol followed by IL-17 blockade for progressive refractory IgA nephropathy patients.

  Uriol-Rivera MG, Obrador-Mulet A, Juliá MR, Daza-Cajigal V, Delgado-Sanchez O, Garcia Alvarez A, Gomez-Lobon A, Carrillo-Garcia P, Saus-Sarrias C, Gómez-Cobo C, Ramis-Cabrer D, Gasco Company J, Molina-Infante J; Balear IgA Research and Treatment Project. Uriol-Rivera MG, et al. Sci Rep. 2024 Feb 28;14(1):4866. doi: 10.1038/s41598-024-55425-7. Sci Rep. 2024. PMID: 38418932 Free PMC article.